Ann: NUZ-001 Shows Positive Results in Human 3D Brain Model, page-12

The Value of Pre-Clinical Indications are just that Peetee,,, they are an indication that requires further trialing... these are great results as they are in the current wheelhouse of MND ALS Parkinson Dementia... BUT we have a Vault full of these with 28 Human Cancers tested by the Olivia Newtown John Foundation , Covid SARs 1 and SARs1 with WEHI , BIOlabs 360 and Leiden plus HVTL1 ,
My guestimate is PAA/NUZ have secured circa 100 Patents , a swag were bought early on in the development of PAA

PharmAust secures broad patent coverage for non-cancer applications
17 May 2017 – Perth, Australia: PharmAust (ASX: PAA), a clinical-stage oncology company,
is pleased to announce the grant of a new patent in Australia covering the use of its lead drug
for non-cancer applications, including neurodegenerative diseases, diabetes and age-related
disorders.
The patent (AU 2013302209), entitled “Compounds For The Treatment Of mTOR
Pathway Related Diseases”, relates to the use of aminoacetonitrile derivatives (AADs) for
the treatment of mTOR pathway-related diseases and provides the company with protection
for this IP until 2033.
‘Aminoacetonitrile derivatives’ include the Novartis Animal Health compound, Monepantel
(MPL) the use of which PharmAust has patented for various disease indications and which is
currently being evaluated in clinical trials for cancer by PharmAust.

Dr Richard Hopkins, PharmAust’s CEO commented “We are delighted with this grant of the
“Method of Use” patent. In addition to our already granted patents covering the use of AADs
to treat cancer, PharmAust has now secured a strong IP position for these compounds for
treatment of non-cancer indications such as neurodegenerative diseases, diabetes and age related disorders. There is increasing evidence that the mTOR pathway plays a major role in
these diseases.
The key message is this patent expands the range of therapeutic indications we can target,
enabling the company to explore new commercial opportunities in major markets”.
Enquiries:
Dr Richard Hopkins
CEO Executive Chairman
Tel: 0405 656 868 Tel: 0402 762 204
[email protected]

So unless NUZ have planned a suite of new trials for the above indications ,,they are just that "Indications" MT has stated this will increase the Value of NUZ having these completed ....

It all comes down to the media push over the next 3 days to move the needle ..

Again additional Data with Preclinicals is far better than a failed Pre Clinical ...

Update is required on the Mouse and K9 data the FDA Require for the IND .NZT